A Common Variant of the Methylene tetrahydrofolate Reductase Gene (1p36) Is Associated with an Increased Risk of Cancer

Bastiaan T. Heijmans, Jolanda M. A. Boer, H. Eka D. Suchiman, Cees J. Cornelisse, Rudi G. J. Westendorp, Daan Kromhout, Edith J. M. Feskens, and P. Eline Slagboom

Molecular Epidemiology Section, Department of Medical Statistics and Bioinformatics [R. T. H., H. E. D. S., P. E. S.], Gerontology and Geriatrics Section, Department of General Internal Medicine [R. G. J. W.], and Department of Pathology [C. J. C.], Leiden University Medical Centre, 2300 RA Leiden, the Netherlands, and Department of Nutrition and Health, National Institute of Public Health and the Environment, 3720 BA Bilthoven [J. M. A. B., D. K., E. J. M. F.], the Netherlands

ABSTRACT

Folate metabolism is thought to play an important role in carcinogenesis through its involvement in both DNA methylation and nucleotide synthesis. A common Ala\(^{222}\)/Val variant in the *methylenetetrahydrofolate reductase* (*MTHFR*) gene leads to a disturbed folate metabolism and is associated with decreased genomic DNA methylation. We previously reported that the *MTHFR* Val/Val genotype was associated with increased cancer mortality in men from a population-based cohort of subjects older age. In conclusion, our current and previous studies in two independent populations indicate that a common Ala/Val variant in the *MTHFR* genotype is a risk factor for cancer in elderly men from the general population. The mechanism underlying this association might involve genomic instability as a result of insufficient methylation of genomic DNA.

INTRODUCTION

Epidemiological studies implicated low folate status in the development of cancer in several organs, including the cervix, colorectum, lung, brain, pancreas, and breast (1). These observations may be explained by the crucial role of folate as the donor of one-carbon units for DNA methylation and nucleotide synthesis. In humans, folate deficiency induces decreased DNA methylation (2), which is a nearly universal feature of early tumorigenesis (1). Insufficient methylation of DNA may promote carcinogenesis by the derepression of proto-oncogenes (3, 4) or by the induction of genomic instability (5). Folate is additionally required for the conversion of the nucleotide dUMP to dTMP. An unbalanced nucleotide pool caused by folate deficiency is associated with an increased occurrence of chromosome breaks as a result of the simultaneous removal and repair of adjacent misincorporated uracil bases on opposing DNA strands (6, 7) and may thereby contribute to cancer risk (8).

MTHFR\(^{3}\) is a key enzyme in folate metabolism and converts 5,10-methylenetetrahydrofolate to 5-methylTHF (Fig. 1). The latter form of folate is used for the remethylation of homocysteine to methionine. DNA methylation is dependent on the synthesis of methionine because its activated form, \(\text{S}-\text{adenosyl}-\text{methionine}\), is the methyl donor in this reaction. If not reduced to 5-methylTHF by MTHFR, 5,10-methylenetetrahydrofolate can transfer its methylene group to dUMP to synthesize dTMP or may contribute to purine synthesis. A common alanine 222-to-valine (Ala/Val) variant of the *MTHFR* gene was found to decrease the activity of the enzyme by 70% in homoygotes for the Val-allele (Ref. 9; ~10% of the general population) and leads to a shift in the distribution of different forms of THF at the expense of 5-methylTHF (10). As is consistent with a diminished availability of 5-methylTHF, the Val/Val genotype is associated with elevated plasma homocysteine levels (11) and decreased genomic DNA methylation (12). As yet there is, however, no evidence for a higher resistance to uracil misincorporation associated with the Val/Val genotype (13).

In a previous study, we presented evidence that the Val/Val genotype was associated with a higher mortality rate in men but not women ages \(\geq\) 85 years and that this observation could be attributed to an increased risk of cancer (14). Later, the Val/Val genotype was also found to be associated with an increased prevalence of gastric cancer (15), colorectal cancer with microsatellite instability (16), and cervical dysplasia (17). In contrast, the Val/Val genotype was observed to reduce the risk of colorectal cancer (18, 19) and acute lymphocytic leukemia (20, 21) in other studies. It thus remains unclear which of the putative effects of the genotype, either the deleterious influence on methylation or the advantageous influence on nucleotide synthesis, prevails in determining cancer risk in the general population. Therefore, we examined the association of the *MTHFR* genotype with the risk of cancer in a population-based prospective study among elderly men (the Zutphen Elderly Study; Ref. 22).

MATERIALS AND METHODS

Subjects. The Zutphen Elderly Study is a population-based, longitudinal investigation of risk factors for chronic diseases in elderly men (22). It is an extension of the Dutch contribution to the Seven Countries Study. In 1985, the 555 survivors of the original cohort of 878 and a random sample of 711 men of the same age (65–84 years) also living in Zutphen were approached. Of those invited 74% (939 of 1266), entered the study: 62 had moved or could not be reached; 109 could not be examined because of serious illness; and 156 refused. Complete information on genotype and standard risk factors was available for 860 men and for 804 men, information on diet was also available. The study was approved by the Medical Ethics Committee of Leiden University and informed consent was obtained from all participants.

Baseline Examinations. Baseline medical and diet examinations were carried out between March and June 1985 (22). Information on smoking status and the prevalence of cancer was obtained by a standardized medical ques-

Received 8/12/02; accepted 1/16/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by the Netherlands Organization for Health, Research and Development Grant 2100.0023, grants from the Netherlands Prevention Foundation, the National Institute on Aging USA, and the Netherlands Heart Foundation Grant 98.067 (to J. M. A. B.)

2 To whom requests for reprints should be addressed, at Molecular Epidemiology, Leiden University Medical Centre, P. O. Box 9503, 2300 RA Leiden, the Netherlands. E-mail: b.t.heijmans@lumc.nl.

3 The abbreviations used are: MTHFR, methylenetetrahydrofolate reductase; 5-methylTHF, 5-methylthrehydrofolate; CI, confidence interval; RR, relative risk; THF, tetrahydrofolate.
tionnaire. Data on baseline prevalence of all cancers were verified with hospital discharge data and written information from the general practitioner. Usual food intake of the participants in the month before the interview was recorded by trained dieticians who used a cross-check dietary history method adapted to the Dutch setting (23). The validity and reproducibility of this method is well established (23, 24). The procedure included a 1-h interview with the participant and the person who prepared the food, the result of which was verified with the quantities of food purchased for the family during a week. On the basis of these data, the daily folate and alcohol intake were estimated using a computerized version of the Netherlands food table. For the estimation of folate intake, recent liquid chromatography data for the folate content of foods were used (25).

Longitudinal Disease Ascertainment. Information on vital status of the participants until January 1995 was obtained from municipal population registries. One man was lost to follow-up in 1989, and 3 men were lost to follow-up in 1991 because they had moved abroad or moved with unknown destination. These men were included in the analyses but censored at July 20, 1989, or December 31, 1990. The incidence of nonfatal cancer during follow-up was recorded at examinations in 1990 and 1995 using standardized questionnaires for responders and an additional short disease questionnaire for nonresponders. Data on incidence of all cancers were verified with hospital discharge data and written information from the general practitioner. Information on fatal cases of cancer was obtained from the Netherlands Central Bureau of Statistics for deaths that occurred between the baseline assessment and June 1990 and from the subjects’ general practitioners for deaths that occurred thereafter. Cancer deaths were verified using hospital data. A single physician coded death from cancer according to the ninth revision of the International Classification of Diseases. Death from any cancer was defined by the ninth revision of the International Classification of Diseases codes 140—209 from lung cancer by 162, from prostate cancer by 185, from colorectal cancer by 153. No cells were lost to follow-up after the diagnosis of cancer. Moreover, possible changes in diet occurring after the diagnosis of cancer. Therefore, 10% of the 50-μl whole genome amplification step. Four inconsistencies were observed (correspondence rate 97%), which may be because of PCR artifacts. It, however, cannot be excluded that these were caused by logistical problems because blood for genomic DNA extraction was collected 5 years later than the serum samples (1990 and 1985, respectively). It is important to note that the differences did not follow a specific pattern. Such random misclassification is expected to lead to underestimated the strength of associations and not to false-positive associations.

Statistical Analysis. Differences in baseline characteristics according to MTHFR genotype were evaluated using ANOVA for normally distributed variables, the Kruskal-Wallis test for variables with a skewed distribution and an overall $\chi^2$ test for categorical variables. Odds ratios for cancer at baseline were estimated using logistic regression. In the follow-up study, associations between MTHFR genotypes and cancer risk were tested using Cox proportional hazards models. For evaluating the previously suggested interaction between the MTHFR genotype and the intake of folate and alcohol (18, 19), prevalent and incident cases of cancer were combined to increase the power of the analysis. Prevalent and incident cases had a similar folate ($P = 0.26$) and alcohol ($P = 0.62$) intake, which indicates that no major changes in diet occurred after the diagnosis of cancer. Moreover, possible changes in diet toward higher folate and lower alcohol intakes would lead to an underestimation of the interaction. Subjects were divided according to the tertile of folate and alcohol intake, and subjects in the two highest tertiles of alcohol intake and the two lowest tertiles of alcohol intake were grouped. Grouping of tertiles was done on the basis of previous studies indicating that the Val/Val genotype was associated with elevated plasma homocysteine at very low intake of folate only (28) and that the Val/Val genotype was associated with an increased risk of colorectal cancer in the high alcohol consumption group and with a decreased risk in the two lower alcohol consumption groups (18). To evaluate the influence of age, the same approach was used but now the subjects were divided according to the median age. All tests were two-sided and values of $P < 0.05$ were considered statistically significant. The analyses were performed using SAS version 6.12.

RESULTS

Table 1 shows the baseline characteristics of the studied cohort of 860 men ages 65–84 years according to MTHFR genotype. The MTHFR genotype distribution was 49.4% (Ala/Ala), 42.1% (Ala/Val), and 8.5% (Val/Val) and was in Hardy-Weinberg equilibrium. The distributions of risk factors for cancer were similar for the different MTHFR genotypes.

As expected, the Val/Val genotype was strongly associated with

| Table 1 Baseline characteristics of men ages 65–84 years according to MTHFR genotype |
|------------------------------------------|----------------------------------|-----------------|--------|
|                                     | Ala/Ala | Ala/Val | Val/Val | $P$   |
| Number (yr)$^a$                     | 425    | 362     | 73      | 0.90  |
| Age (yr)$^a$                        | 71.5 (5.3) | 71.4 (5.5) | 71.2 (5.3) | 0.09  |
| Body mass index, kg/m$^2$           | 25.5 (3.2) | 25.5 (3.2) | 25.2 (2.9) | 0.75  |
| Smoking status$^a$                  | 0.36   |         |         |       |
| Current smokers, %                  | 29.5   | 30.9    | 32.9    | 0.26  |
| Former smokers, %                   | 50.0   | 50.3    | 57.5    | 0.18  |
| Never smokers, %                    | 19.0   | 18.8    | 9.6     | 0.01  |
| Alcohol intake, g/day$^a$           | 13.5 (17.4) | 12.7 (16.4) | 16.5 (18.4) | 0.24  |
| Folate intake, µg/day$^a$           | 201 (61) | 202 (63) | 192 (55) | 0.49  |

$^a$ Values in parentheses for variables are SDs.

$^b$ Range 65–84 years.

$^c$ Missing data on smoking for 1 of 860 subjects.

$^d$ Missing data on folate and alcohol intake for 56 of 860 subjects.
elevated total plasma homocysteine levels ($P = 0.0001$; Table 2). For subjects homozygous for the Ala-allele, the mean level was 14.8 mmol/ml, whereas it was 21.6 mmol/ml among subjects homozygous for the Val/Val genotype (Table 2). This association was significantly modulated by folate intake ($P$, interaction $= 0.0006$; Table 2).

The baseline prevalence of cancer among subjects homozygous for the Val-allele (11.0%) tended to be higher than among those homozygous for the Ala-allele (6.1%), although this was not statistically significant ($P = 0.17$; data not shown). The risk of cancer associated with the Val/Val genotype as estimated with the odds ratio was 1.95 (95% CI, 0.84–4.54) compared with the Ala/Ala genotype.

During the 10-year follow-up period, 149 new cases of cancer occurred among the 793 men without cancer at baseline. The most common sites where cancer developed were the lung (27%), prostate (15%), colorectum (12%), and the kidney or bladder (10%). Compared with men homozygous for the common Ala-allele, the age-adjusted risk of cancer was 1.80-fold (95% CI, 1.09–3.00) increased among men with the Val/Val genotype (Table 3). Additional adjustment for smoking status (RR, 1.77; 95% CI, 1.06–2.94) or smoking status, body mass index, and alcohol and folate intake (RR, 1.64; 95% CI, 0.96–2.80; missing data for 54 subjects) did not appreciably alter this risk estimate. The analysis of the four common forms of cancer revealed that the higher incidence of cancer was because of significantly increased risks of cancer of the prostate, colorectum, and kidney or bladder, whereas the risk of lung cancer remained unaffected (Table 3).

On the basis of previously published reports (18, 19), we next evaluated the influence of folate and alcohol intake on the association between the Val/Val genotype and cancer risk (Table 4). To increase the power of the analysis we combined prevalent ($n$ in the power of the analysis we combined prevalent $n$) and incident ($n = 149$) cases of cancer (see “Materials and Methods”).

Among men whose folate intake was $\leq 169.8$ µg/day, the Val/Val genotype was associated with a 2.64-fold increased risk of cancer as compared with a 1.60-fold increased risk among men with a higher folate intake. Among men who consumed $>14$ g of alcohol/day, the Val/Val genotype was associated with a 2.27-fold increased risk of cancer as compared with a 1.63-fold increased risk among men with a lower alcohol consumption. Furthermore, the risk of cancer associated with the Val/Val genotype was 3.14-fold increased among men older than the median age of 71 years, whereas the risk was only 1.37-fold increased among younger men (Table 4).

### DISCUSSION

We studied the influence of a common MTHFR Ala/Val polymorphism on the risk of cancer in a population-based cohort of men ages 65–84 years old. Consistent with the hypothesis that the Val/Val genotype contributes to a disturbed folate metabolism in vivo, the genotype was associated with considerably elevated levels of plasma homocysteine, particularly among those with lower folate intakes. Over a 10-year follow-up period, the Val/Val genotype was associated with a $\sim 2$-fold increased risk of cancer. A similar 2-fold increase in risk was observed in the comparison of cancer at baseline, although this was not statistically significant.

Investigation of common forms of cancer revealed that, although the numbers were small, the incidences of cancer of the prostate, the colorectum and the kidney or bladder were significantly increased among men with the Val/Val genotype, whereas the risk of lung cancer was not affected possibly because the large effect of smoking overrides milder risk factors. The latter finding is in agreement with our unpublished results that the Val/Val genotype frequency was not increased among 211 lung cancer patients (11.4%) as compared with 250 controls (12.4%) and a previous report (29).

Our finding that the MTHFR variant is associated with an increased risk of cancer in elderly men from the general population confirms our earlier observation in a population-based study among subjects...
The deleterious effects of the Val/Val genotype. Additionally, age differences were observed in male American health professionals and acute lymphocytic leukemia (20, 21). The protective effect of the Val/Val genotype was attributed to an associated deleterious effect on cancer risk. The mechanism underlying this association may involve a decreased DNA methylation as a result of a disturbed folate metabolism. We hypothesize that genome-wide hypomethylation promoting genomic instability (5) rather than gene-specific effects such as derepression of proto-oncogenes (3, 4) is relevant in this respect.

ACKNOWLEDGMENTS

We thank Professor Coen D. A. Stehouwer and his staff at the Free University Medical Centre in Amsterdam, the Netherlands, for determining plasma homocysteine levels.

REFERENCES


A Common Variant of the Methylenetetrahydrofolate Reductase Gene (1p36) Is Associated with an Increased Risk of Cancer


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/6/1249

Cited articles  This article cites 35 articles, 22 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/6/1249.full.html#ref-list-1

Citing articles  This article has been cited by 24 HighWire-hosted articles. Access the articles at:
/content/63/6/1249.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.